. Author manuscript; available in PMC: 2011 Jul 1.

Published in final edited form as: Int J Neuropsychopharmacol. 2011 Jan 28;14(6):756–767. doi: 10.1017/S1461145710001689

Table 2.

Descriptive statistics for metabolites in tryptophan pathway

Metabolites	HC (n=30)	FENNS-BL (n=25)	FENNS-4w (n=25)	p values
Metabolites	HC (n=30)	FENNS-BL (n=25)	FENNS-4w (n=25)	HC vs. BL	HC vs. 4w	BL vs. 4w
TRP	7628±3043^a	6426±3493	5469±2977	0.069	0.007^b	0.133
5-HT	200±145	238±152	182±147	0.301	0.562	0.020
5-HIAA	18±11	19±16	17±21	0.496	0.014	0.263
MEL	1.03±0.44	0.80±0.39	0.70±0.34	0.073	0.003^b	0.156
KYN	161±86	125±79	111±75	0.077	0.013	0.287
3-OHKY	10±8	8.17±8.10	7.73±8.75	0.176	0.071	0.751
TRPA	19±7	17±9	16±6	0.144	0.175	0.791

HC, Healthy controls ; FENNS, first-episode neuroleptic-naive patients with schizophrenia ; BL, baseline ; 4w, 4-wk treatment with antipsychotic drugs; TRP, tryptophan; 5-HT, serotonin; 5-HIAA, 5-hydroxyindoleacetic acid ; MEL, melatonin; KYN, kynurenine ; 3-OHKY, 3-hydroxykynurenine; TRPA, tryptamine.

Each value (ng/ml) represents mean and standard deviation. All data were adapted from Yao et al. (2010a).

Because the parametric assumptions for the Student’s t test are not met, a non-parametric test, the Wilcoxon Rank Sum test was used to compare the locations of samples from disparate groups, and the Wilcoxon Signed Rank test was done to compare paired samples (i.e. BL vs. 4w). Significant difference after Bonferroni correction of an α of 0.05–0.0038, or 0.10–0.0077.